Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine pilot study for delirium after stroke
NL-OMON28018Active, not recruiting
- Sponsor
- Novartis
- Start
- Feb 2004
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of rivastigmine in delirium, sponsored by Novartis. Primary endpoints: Presence of delirium and Delirium severity. Started Feb 2004; status: active, not recruiting.
02
Drugs
rivastigmine
03
Conditions
delirium
Beyond the preview
Go deeper on NL-OMON28018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28018.